Skip to main content
Exercise Treatment for Major Depression: Maintenance of Therapeutic Benefit at 10 Months
Psychosomatic Medicine
  • Michael Babyak
  • James Blumenthal
  • Steve Herman
  • Parinda Khatri
  • Murali Doraiswamy
  • Kathleen A. Moore, University of South Florida
  • W. Edward Craighead
  • Teri Baldewicz
  • K. Ranga Krishnan
Document Type
Publication Date

Objective: The purpose of this study was to assess the status of 156 adult volunteers with major depressive disorder (MDD) 6 months after completion of a study in which they were randomly assigned to a 4-month course of aerobic e-ercise, sertraline therapy, or a combination of e-ercise and sertraline.

Methods: The presence and severity of depression were assessed by clinical interview using the Diagnostic Interview Schedule and the Hamilton Rating Scale for Depression (HRSD) and by self-report using the Beck Depression Inventory. Assessments were performed at baseline, after 4 months of treatment, and 6 months after treatment was concluded (ie, after 10 months).

Results: After 4 months patients in all three groups e-hibited significant improvement; the proportion of remitted participants (ie, those who no longer met diagnostic criteria for MDD and had an HRSD score <8) was comparable across the three treatment conditions. After 10 months, however, remitted subjects in the e-ercise group had significantly lower relapse rates (p = .01) than subjects in the medication group. Exercising on one’s own during the follow-up period was associated with a reduced probability of depression diagnosis at the end of that period (odds ratio = 0.49, p = .0009).

Conclusions: Among individuals with MDD, e-ercise therapy is feasible and is associated with significant therapeutic benefit, especially if e-ercise is continued over time.

Citation / Publisher Attribution

Psychosomatic Medicine, v. 62, issue 5, p. 633-638

Citation Information
Michael Babyak, James Blumenthal, Steve Herman, Parinda Khatri, et al.. "Exercise Treatment for Major Depression: Maintenance of Therapeutic Benefit at 10 Months" Psychosomatic Medicine Vol. 62 Iss. 5 (2000) p. 633 - 638
Available at: